Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis
Purpose: The aim isevaluation of the efficacy of triple therapy of sofosbuvir, pegylated INFalpha 2a and ribavirin in
treatment of chronic hepatitis C (CHC) patientsgenotype
4 who have high fibrosis. Materials and Methods: Fifty HCV patients with high
fibrosis (F3 & F4) were included in the study. Results: SVR rate was 54%; non-responders rate was 12% and relapsers rate was
34%. When comparing SVR between F3 group patients and F4 group, it was 88% and 66% respectively, which means that SVR was
higher in the F3 group. Conclusion: Triple therapy including pegylated INFalpha
2a is not an ideal therapy in treatment of CHC patients genotype 4 with
cirrhosis because of low sustained virological response rates and high
incidence of side effects.
References
[1]
Amer, F.A., Gohar, M. and Yousef, M. (2015) Epidemiology of Hepatitis C Virus Infection in Egypt. International Journal of TROPICAL DISEASE & Health, 7, 119-131. https://doi.org/10.9734/IJTDH/2015/15727
[2]
Sanaa M.K. (2011) Hepatitis C Virus Genotype 4 Therapy: Progress and Challenges. Liver International, 31, 45-52. https://doi.org/10.1111/j.1478-3231.2010.02385.x
[3]
Cure, S., Guerra, I. and Dusheiko, G. (2015) Cost-Effectiveness of Sofosbuvir for the Treatment of Chronic Hepatitis C-Infected Patients. Journal of Viral Hepatitis, 22, 882-889. https://doi.org/10.1111/jvh.12409
[4]
Yousra, A.M., Ghina, R.M. and Laith, J.A. (2013) The Epidemiology of Hepatitis C Virus Infection in Egypt: A Systematic Review and Data Synthesis. BMC Infectious Diseases, 13, 288. https://doi.org/10.1186/1471-2334-13-288
[5]
Pybus, O.G., Drummond, O.J., Nakano, T., et al. (2002) The Epidemiology and Iatrogenic Transmission of Hepatitis C Virus in Egypt: A Bayesian Coalescent Approach. Molecular Biology and Evolution, 20, 381-387. https://doi.org/10.1093/molbev/msg043
[6]
Frank, C., Dipl, G., Mostafa, K.M., et al. (2000) The Role of Parenteral Antischistosomal Therapy in the Spread of Hepatitis C Virus in Egypt. The Lancet, 355, 887-891. https://doi.org/10.1016/S0140-6736(99)06527-7
[7]
Eric, L., Alessandra, M., David, W., et al. (2013) Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. The New England Journal of Medicine, 368, 1878-1887. https://doi.org/10.1056/NEJMoa1214853
[8]
Montserrat, L., Carmen, C., Javier, M., et al. (2009) Randomized Trial Comparing Pegylated Interferon 2b Versus Pegylated Interferon 2a, Both Plus Ribavirin, to Treat Chronic Hepatitis C in Human Immunodeficiency Virus Patients. Hepatology, 49, 22-310. https://doi.org/10.1002/hep.22598
